Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 42% Improvement Relative Risk Colchicine  Villamañán et al.  LATE TREATMENT Is late treatment with colchicine beneficial for COVID-19? Retrospective 222 patients in Spain (March - June 2020) Lower mortality with colchicine (p=0.031) c19early.org Villamañán et al., Section 4: Clinical.., Mar 2023 Favors colchicine Favors control

Targeting patients with pneumonia by COVID-19 that could be beneficiated by colchicine

Villamañán et al., Section 4: Clinical pharmacy services, doi:10.1136/ejhpharm-2023-eahp.56
Mar 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.0000001 from 54 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Retrospective 111 hospitalized COVID-19 pneumonia patients treated with colchicine and 111 matched controls, showing lower mortality with colchicine treatment.
risk of death, 41.9% lower, RR 0.58, p = 0.03, treatment 19 of 111 (17.1%), control 32 of 111 (28.8%), NNT 8.5, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Villamañán et al., 23 Mar 2023, retrospective, Spain, peer-reviewed, median age 79.0, 10 authors, study period March 2020 - June 2020.
This PaperColchicineAll
Abstract: 4CPS-007 TARGETING PATIENTS WITH PNEUMONIA BY COVID- 4CPS-008 DOES COMORBIDITY AFFECT ADHERENCE TO 19 THAT COULD BE BENEFICIATED BY COLCHICINE 1 1 1 1 1 1 INHALERS IN SEVERE ASTHMA PATIENTS TREATED WITH BIOLOGICS? 2 E Villamañán*, C Sobrino, C Mateos, V Collada, A Hoyo, S Mallón, J Pavón, I Jiménez, 3Y Larrubia, 1A Herrero. 1Hospital Universitario la Paz, Pharmacy, Madrid, Spain; 2 Hospital Universitario la Paz, Pneumology, Madrid, Spain; 3Hospital Infanta Sofía, Pharmacy, Madrid, Spain 1 1 10.1136/ejhpharm-2023-eahp.56 10.1136/ejhpharm-2023-eahp.57 Background and Importance Available data reported different results about the effect of colchicine in patients with COVID19 pneumonia (CN) proving the need for more analysis. Currently, many of these patients are treated with high-cost new drugs with poor results. Aim and Objectives To evaluate whether treatment with colchicine added to the standard therapy for CN was related to deaths reduction. Secondary objectives: to analyse differences in length of stay (LOS) and combination of drugs in treatment protocols with better results. Material and Methods Multicentre, real-world, controlled, retrospective cohort study(March-June2020). Inclusion criteria: hospitalised adult patients with CN. Admitted to critical care units were excluded. Experimental group: Patients treated with colchicine who met inclusion criteria (colchicine therapy group [CG]). Control group: those who met inclusion criteria and did not received colchicine (non-colchicine therapy group [NCG]). Patients were matched 1:1 by age ( ± 2years), sex, severity of the disease and comorbidity. To select controls, we chose the consecutively next admitted patient after one treated with colchicine. This allowed us to select control subjects at a close time and place to cases, that is, under similar circumstances in terms of patient care protocols. Results 222 (111 treated with colchicine) patients were analysed. Median age 79 years [66–88] (81 years [66-87] in CG vs 79 years [66-88] in NCG, p=0.978). 52.3% men (54.1% CG vs 50.5% NCG; p=0.591). Primary endpoint of death occurred in 19 (17.1%) patients in the CG as compared with 32 (29.4%) in the NCG (OR: 0.497; 95% CI: 0.261–0.946; p=0.031). Hospital LOS was dichotomised by the median value (10 days), the use of colchicine was associated with a longer hospital LOS when comparing with the control group (OR=1.856; 95% CI:1.089–3.162; p=0.022). Proportion of deaths were higher in NCG than in CG in patients 70 years (p=0.012). With respect to sex and comorbidity, distribution of deaths showed no significant differences. Almost all patients received antimicrobials (91.9%) concomitantly, death rate: 19/ 50 (38%) CG vs.31/50 (62%) NCG; p=0.023), by antimicrobial: azithromycin (9/19) (47.4%) in CG vs.10/19 (52.6%) NCG; p=0.517; ceftriaxone16/44 (36.4%) CG vs 28/44 (63.6%) NCG; p=0.022 and levofloxacin 4/12 (33.3%) CG vs 8/12 (66.7%) NCG; p=0.232. Conclusion and Relevance Our study showed lower mortality in hospitalised patients who received colchicine to treat CN. This treatment was particularly beneficial for elderly treated with antibiotics concomitantly. Findings in our study support the need of more randomised clinical trials that could fully elucidate the type of patients who may potentially benefit from this low-cost drug. Background and Importance Comorbidities are often associated with severe asthma including those patients treated with biologics. That often contributes to..
{ 'DOI': '10.1136/ejhpharm-2023-eahp.56', 'URL': 'http://dx.doi.org/10.1136/ejhpharm-2023-eahp.56', 'alternative-id': ['10.1136/ejhpharm-2023-eahp.56'], 'author': [ {'affiliation': [], 'family': 'Villamañán', 'given': 'E', 'sequence': 'first'}, {'affiliation': [], 'family': 'Sobrino', 'given': 'C', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mateos', 'given': 'C', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Collada', 'given': 'V', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Hoyo', 'given': 'A', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mallón', 'given': 'S', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Pavón', 'given': 'J', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Jiménez', 'given': 'I', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Larrubia', 'given': 'Y', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Herrero', 'given': 'A', 'sequence': 'additional'}], 'container-title': 'Section 4: Clinical pharmacy services', 'content-domain': {'crossmark-restriction': True, 'domain': ['bmj.com']}, 'created': {'date-parts': [[2023, 3, 23]], 'date-time': '2023-03-23T09:35:38Z', 'timestamp': 1679564138000}, 'deposited': { 'date-parts': [[2023, 3, 23]], 'date-time': '2023-03-23T09:40:21Z', 'timestamp': 1679564421000}, 'event': '27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023', 'indexed': {'date-parts': [[2023, 3, 24]], 'date-time': '2023-03-24T04:50:42Z', 'timestamp': 1679633442670}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2023, 3]]}, 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/ejhpharm-2023-eahp.56', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '239', 'original-title': [], 'prefix': '10.1136', 'published': {'date-parts': [[2023, 3]]}, 'published-online': {'date-parts': [[2023, 3, 23]]}, 'published-print': {'date-parts': [[2023, 3]]}, 'publisher': 'British Medical Journal Publishing Group', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': {'primary': {'URL': 'https://ejhp.bmj.com/lookup/doi/10.1136/ejhpharm-2023-eahp.56'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subtitle': [], 'title': '4CPS-007\u2005Targeting patients with pneumonia by COVID-19 that could be beneficiated by ' 'colchicine', 'type': 'proceedings-article', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit